Biological gene delivery vehicles: Beyond viral vectors

Molecular Therapy

Volumn 17, Issue 5, 2009, Pages 767-777

  Seow, Yiqi ^a   Wood, Matthew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VECTOR; BACULOVIRUS VECTOR; LIPOSOME; PLASMID VECTOR; VIRUS VECTOR;

ANTIBODY PRODUCTION; BACTERIAL STRAIN; BACTERIOPHAGE; ERYTHROCYTE GHOST; EXOSOME; GENE EXPRESSION SYSTEM; GENE VECTOR; HUMAN; IMMUNE RESPONSE; IN VIVO GENE TRANSFER; LIPOSOMAL GENE DELIVERY SYSTEM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS LIKE AGENT;

BACTERIA; BACTERIOPHAGES; ERYTHROCYTE MEMBRANE; EXOSOMES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; VIRUSES;

EID: 67349204836     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.41     Document Type: Review

References (133)

1. Takakura, Y, Nishikawa, M, Yamashita, F and Hashida, M (2001). Development of gene drug delivery systems based on pharmacokinetic studies. Eur J Pharm Sci 13: 71-76.
2. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
3. Kawabata, K, Takakura, Y and Hashida, M (1995). The fate of plasmid DNA after intravenous injection in mice: Involvement of scavenger receptors in its hepatic uptake. Pharm Res 12: 825-830.
4. Liu, F, Shollenberger, LM and Huang, L (2004). Non-immunostimulatory nonviral vectors. FASEB J 18: 1779-1781.
5. Gene therapy Clinical Trials Worldwide. . Accessed 9 September 2008.
6. Lowenstein, PR, Mandel, RJ, Xiong, WD, Kroeger, K and Castro, MG (2007). Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: The role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 7: 347-360.
7. Alexander, IE, Cunningham, SC, Logan, GJ and Christodoulou, J (2008). Potential of AAV vectors in the treatment of metabolic disease. Gene Ther 15: 831-839.
8. Hasbrouck, NC and High, KA (2008). AAV-mediated gene transfer for the treatment of hemophilia B: Problems and prospects. Gene Ther 15 870-875.
9. Daniel, R and Smith, JA (2008). Integration site selection by retroviral vectors: Molecular mechanism and clinical consequences. Hum Gene Ther 19: 557-568.
10. Zhang, JS, Liu, F and Huang, L (2005). Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 57: 689-698.
11. Jiang, H, Couto, LB, Patarroyo-White, S, Liu, T, Nagy, D, Vargas, JA et al. (2006). Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108: 3321-3328.
12. Wang, Z, Kuhr, CS, Allen, JM, Blankinship, M, Gregorevic, P, Chamberlain, JS et al. (2007). Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15: 1160-1166.
13. Li, JZ, Li, H, Hankins, GR, Dunford, B and Helm, GA (2005). Local immunomodulation with CD4 and CD8 antibodies, but not cyclosporine A, improves osteogenesis induced by ADhBMP9 gene therapy. Gene Ther 12: 1235-1241.
14. Zaiss, AK and Muruve, DA (2005). Immune responses to adeno-associated viral vectors. Curr Gene Ther 5: 323-331.
15. Lufino, MM, Edser, PA and Wade-Martins, R (2008). Advances in high-capacity extrachromosomal vector technology: Episomal maintenance, vector delivery, and transgene expression. Mol Ther 16: 1525-1538.
16. Taylor, N, Uribe, L, Smith, S, Jahn, T, Kohn, DB and Weinberg, K (1996). Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the γ-c gene. Blood 87: 3103-3107.
17. Smith, AJ, Schlichtenbrede, FC, Tschernutter, M, Bainbridge, JW, Thrasher, AJ and Ali, RR (2003). AAV-mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol Ther 8: 188-195.
18. Oh, YK, Sohn, T, Park, JS, Kang, MJ, Choi, HG, Kim, JA et al. (2004). Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. Virology 328: 266-273.
19. Williams, DA (2007). RAC reviews serious adverse event associated with AAV therapy trial. Mol Ther 15: 2053-2054.
20. Irshad, M, Joshi, YK, Sharma, Y and Dhar, I (2006). Transfusion transmitted virus: A review on its molecular characteristics and role in medicine. World J Gastroenterol 12: 5122-5134.
21. Fadok, VA, Voelker, DR, Campbell, PA, Cohen, JJ, Bratton, DL and Henson, PM (1992). Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148: 2207-2216.
22. Valadi, H, Ekström, K, Bossios, A, Sjöstrand, M, Lee, JJ and Lötvall, JO (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659.
23. Castagliuolo, I, Beggiao, E, Brun, P, Barzon, L, Goussard, S, Manganelli, R et al. (2005). Engineered E. coli delivers therapeutic genes to the colonic mucosa. Gene Ther 12: 1070-1078.
24. Grillot-Courvalin, C, Goussard, S, Huetz, F, Ojcius, DM and Courvalin, P (1998). Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol 16: 862-866.
25. Stritzker, J, Pilgrim, S, Szalay, AA and Goebel, W (2008). Prodrug converting enzyme gene delivery by L. monocytogenes. BMC Cancer 8: 94.
26. Akin, D, Sturgis, J, Ragheb, K, Sherman, D, Burkholder, K, Robinson, JP et al. (2007). Bacteria-mediated delivery of nanoparticles and cargo into cells. Nat Nanotechnol 2: 441-449.
27. Souders, NC, Verch, T and Paterson, Y (2006). In vivo bactofection: Listeria can function as a DNA-cancer vaccine. DNA Cell Biol 25: 142-151.
28. Shen, H, Kanoh, M, Liu, F, Maruyama, S and Asano, Y (2004). Modulation of the immune system by Listeria monocytogenes-mediated gene transfer into mammalian cells. Microbiol Immunol 48: 329-337.
29. Abdul-Wahid, A and Faubert, G (2007). Mucosal delivery of a transmission-blocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella typhimurium bactofection vehicle. Vaccine 25: 8372-8383.
30. Zhao, M, Geller, J, Ma, H, Yang, M, Penman, S and Hoffman, RM (2007). Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 104: 10170-10174.
31. Pawelek, JM, Low, KB and Bermudes, D (1997). Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57: 4537-4544.
32. Toso, JF, Gill, VJ, Hwu, P, Marincola, FM, Restifo, NP, Schwartzentruber, DJ et al. (2002). Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20: 142-152.
33. Nemunaitis, J, Cunningham, C, Senzer, N, Kuhn, J, Cramm, J, Litz, C et al. (2003). Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 10: 737-744.
34. Shiau, AL, Chen, CC, Yo, YT, Chu, CY, Wang, SY and Wu, CL (2005). Enhancement of humoral and cellular immune responses by an oral Salmonella choleraesuis vaccine expressing porcine prothymosin à. Vaccine 23: 5563-5571.
35. Hamaji, Y, Fujimori, M, Sasaki, T, Matsuhashi, H, Matsui-Seki, K, Shimatani-Shibata, Y et al. (2007). Strong enhancement of recombinant cytosine deaminase activity in Bifidobacterium longum for tumor-targeting enzyme/prodrug therapy. Biosci Biotechnol Biochem 71: 874-883.
36. Larsen, MD, Griesenbach, U, Goussard, S, Gruenert, DC, Geddes, DM, Scheule, RK et al. (2008). Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli. Gene Ther 15: 434-442.
37. Xiang, S, Fruehauf, J and Li, CJ (2006). Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 24 697-702.
38. Celec, P, Gardlík, R, Pálffy, R, Hodosy, J, Stuchlík, S, Drahovsk, H et al. (2005). The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor - an alternative gene therapy. Med Hypotheses 64: 505-511.
39. Schoen, C, Kolb-Mäurer, A, Geginat, G, Löffler, D, Bergmann, B, Stritzker, J et al. (2005). Bacterial delivery of functional messenger RNA to mammalian cells. Cell Microbiol 7: 709-724.
40. Scheule, RK (2000). The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 44: 119-134.
41. Pannell, D and Ellis, J (2001). Silencing of gene expression: implications for design of retroviral vectors. Rev Med Virol 11 205-2017.
42. Birmingham, CL, Canadien, V, Kaniuk, NA, Steinberg, BE, Higgins, DE and Brumell, JH (2008). Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles. Nature 451: 350-354.
43. Yu, YA, Shabahang, S, Timiryasova, TM, Zhang, Q, Beltz, R, Gentschev, I et al. (2004). Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 22: 313-320.
44. Zelmer, A, Krusch, S, Koschinski, A, Rohde, M, Repp, H, Chakraborty, T et al. (2005). Functional transfer of eukaryotic expression plasmids to mammalian cells by Listeria monocytogenes: A mechanistic approach. J Gene Med 7: 1097-1112.
45. Hyde, SC, Pringle, IA, Abdullah, S, Lawton, AE, Davies, LA, Varathalingam, A et al. (2008). CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 26: 549-551.
46. Artis, D (2008). Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 8 411-420.
47. Chatel, JM, Pothelune, L, Ah-Leung, S, Corthier, G, Wal, JM and Langella, P (2008). In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. Gene Ther 15 1184-1190.
48. Tlaskalová-Hogenová H, Stepánková R, Hudcovic, T, Tucková, L, Cukrowska, B, Lodinová-Zádníková R et al. (2004). Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 93: 97-108.
49. Brüssow, H, Fremont, M, Bruttin, A, Sidoti, J, Constable, A and Fryder, V (1994). Detection and classification of Streptococcus thermophilus bacteriophages isolated from industrial milk fermentation. Appl Environ Microbiol 60: 4537-4543.
50. Jepson, CD and March, JB (2004). Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. Vaccine 22: 2413-2419.
51. Larocca, D, Jensen-Pergakes, K, Burg, MA and Baird, A (2001). Receptor-targeted gene delivery using multivalent phagemid particles. Mol Ther 3: 476-484.
52. Lundstrom, K (2003). Latest development in viral vectors for gene therapy. Trends Biotechnol 21: 117-122.
53. Chauthaiwale, VM, Therwath, A and Deshpande, VV (1992). Bacteriophage lambda as a cloning vector. Microbiol Rev 56: 577-591.
54. Greenstein, D and Brent, R (2001). Introduction to vectors derived from filamentous phages. Curr Protoc Mol Biol. Chapter 1:UNit1.14.
55. Kaneda, Y, Saeki, Y, Nakabayashi, M, Zhou, WZ, Kaneda, MW and Morishita, R (2000). Enhancement of transgene expression by cotransfection of oriP plasmid with EBNA-1 expression vector. Hum Gene Ther 11: 471-479.
56. Burg, MA, Jensen-Pergakes, K, Gonzalez, AM, Ravey, P, Baird, A and Larocca, D (2002). Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells. Cancer Res 62: 977-981.
57. Poul, MA and Marks, JD (1999). Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol 288: 203-211.
58. Larocca, D, Witte, A, Johnson, W, Pierce, GF and Baird, A (1998). Targeting bacteriophage to mammalian cell surface receptors for gene delivery. Hum Gene Ther 9: 2393-2399.
59. Mount, JD, Samoylova, TI, Morrison, NE, Cox, NR, Baker, HJ and Petrenko, VA (2004). Cell targeted phagemid rescued by preselected landscape phage. Gene 341: 59-65.
60. Piersanti, S, Cherubini, G, Martina, Y, Salone, B, Avitabile, D, Grosso, F et al. (2004). Mammalian cell transduction and internalization properties of lambda phages displaying the full-length adenoviral penton base or its central domain. J Mol Med 82: 467-476.
61. Molenaar, TJ, Michon, I, de Haas, SA, van Berkel, TJ, Kuiper, J and Biessen, EA (2002). Uptake and processing of modified bacteriophage M13 in mice: Implications for phage display. Virology 293: 182-191.
62. Chen, Y, Shen, Y, Guo, X, Zhang, C, Yang, W, Ma, M et al. (2006). Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol 24: 455-460.
63. Geier, MR, Trigg, ME and Merril, CR (1973). Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246: 221-223.
64. Merril, CR, Biswas, B, Carlton, R, Jensen, NC, Creed, GJ, Zullo, S et al. (1996). Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci USA 93: 3188-3192.
65. Reynaud, A, Cloastre, L, Bernard, J, Laveran, H, Ackermann, HW, Licois, D et al. (1992). Characteristics and diffusion in the rabbit of a phage for Escherichia coli 0103. Attempts to use this phage for therapy. Vet Microbiol 30: 203-212.
66. Shearer, WT, Lugg, DJ, Rosenblatt, HM, Nickolls, PM, Sharp, RM, Reuben, JM et al. (2001). Antibody responses to bacteriophage X-174 in human subjects exposed to the Antarctic winter-over model of spaceflight. J Allergy Clin Immunol 107: 160-164.
67. Ochs, HD, Davis, SD and Wedgwood, RJ (1971). Immunologic responses to bacteriophage ΦX174 in immunodeficiency diseases. J Clin Invest 50: 2559-2568.
68. Bundy, BC, Franciszkowicz, MJ and Swartz, JR (2008). Escherichia coli based cell-free synthesis of virus-like particles. Biotechnol Bioeng 100: 28-37.
69. Wu, M, Sherwin, T, Brown, WL and Stockley, PG (2005). Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine 1: 67-76.
70. Chen, XS, Casini, G, Harrison, SC and Garcea, RL (2001). Papillomavirus capsid protein expression in Escherichia coli: Purification and assembly of HPV11 and HPV16 L1. J Mol Biol 307: 173-182.
71. Huang, Z, Elkin, G, Maloney, BJ, Beuhner, N, Arntzen, CJ, Thanavala, Y et al. (2005). Virus-like particle expression and assembly in plants: Hepatitis B and Norwalk viruses. Vaccine 23: 1851-1858.
72. Garnier, L, Ravallec, M, Blanchard, P, Chaabihi, H, Bossy, JP, Devauchelle, G et al. (1995). Incorporation of pseudorabies virus gD into human immunodeficiency virus type 1 gag particles produced in baculovirus-infected cells. J Virol 69: 4060-4068.
73. O'Neal, CM, Crawford, SE, Estes, MK and Conner, ME (1997). Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol 71: 8707-8717.
74. Sedlik, C, Saron, M-F, Sarraseca, J, Casal, I and Leclerc, C (1997). Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 94: 7503-7508.
75. Guerrero, RA, Ball, JM, Krater, SS, Pacheco, SE, Clements, JD and Estes, MK (2001). Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosa (fecal and vaginal) immune responses. J Virol 75: 9713-9722.
76. Zhang, H, Fayad, R, Wang, X, Quinn, D and Qiao, L (2004). Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag. J Virol 78: 10249-10257.
77. Touzé, A, Bousarghin, L, Ster, C, Combita, AL, Roingeard, P and Coursaget, P (2001). Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells. J Gen Virol 82 3005-3009.
78. Yamada, T, Iwasaki, Y, Tada, H, Iwabuki, H, Chuah, MK, VandenDriessche, T et al. (2003). Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol 21: 885-90.
79. Iwasaki, Y, Ueda, M, Yamada, T, Kondo, A, Seno, M, Tanizawa, K et al. (2007). Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Ther 14: 74-81.
80. Sakuragi, S, Goto, T, Sano, K and Morikawa, Y (2002). HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc Natl Acad Sci USA 99: 7956-7961.
81. Wang, M, Tsou, TH, Chen, LS, Ou, WC, Chen, PL, Chang, CF et al. (2004). Inhibition of simian virus 40 large tumor antigen expression in human fetal glial cells by an antisense oligodeoxynucleotide delivered by the JC virus-like particle. Hum Gene Ther 15: 1077-1090.
82. Touze, A and Coursaget, P (1998). In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 26: 1317-1323.
83. Pattenden, LK, Middelberg, AP, Niebert, M and Lipin, DI (2005). Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol 23: 523-529.
84. Fayad, R, Zhang, H, Quinn, D, Huang, Y and Qiao, L (2004). Oral administration with papillomavirus pseudovirus encoding IL-2 fully restores mucosal and systemic immune responses to vaccinations in aged mice. J Immunol 173: 2692-2698.
85. Shi, W, Liu, J, Huang, Y and Qiao, L (2001). Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 75: 10139-10148.
86. Malboeuf, CM, Simon, DA, Lee, YE, Lankes, HA, Dewhurst, S, Frelinger, JG et al. (2007). Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine 25: 3270-3276.
87. Brandenburg, B, Stockl, L, Gutzeit, C, Roos, M, Lupberger, J, Schwartlander, R et al. (2005). A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle. Hepatology 42: 1300-1309.
88. Takamura, S, Niikura, M, Li, TC, Takeda, N, Kusagawa, S, Takebe, Y et al. (2004). DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther 11: 628-635.
89. Gleiter, S and Lilie, H (2003). Cell-type specific targeting and gene expression using a variant of polyoma VP1 virus-like particles. Biol Chem 384: 247-255.
90. May, T, Gleiter, S and Lilie, H (2002). Assessment of cell type specific gene transfer of polyoma virus like particles presenting a tumor specific antibody Fv fragment. J Virol Methods 105: 147-157.
91. Clark, B, Caparrós-Wanderley, W, Musselwhite, G, Kotecha, M and Griffin, BE (2001). Immunity against both polyomavirus VP1 and a transgene product induced following intranasal delivery of VP1 pseudocapsid-DNA complexes. J Gen Virol 82: 2791-2797.
92. Krauzewicz, N, Stokrová J, Jenkins, C, Elliott, M, Higgins, CF and Griffin, BE (2000). Virus-like gene transfer into cells mediated by polyoma virus pseudocapsids. Gene Ther 7: 2122-2131.
93. Krauzewicz, N, Cox, C, Soeda, E, Clark, B, Rayner, S and Griffin, BE (2000). Sustained ex vivo and in vivo transfer of a reporter gene using polyoma virus pseudocapsids. Gene Ther 7: 1094-1102.
94. Luo, L, Li, Y, Cannon, PM, Kim, S and Kang, CY (1992). Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc Natl Acad Sci USA 89: 10527-10531.
95. Eto, Y, Yoshioka, Y, Mukai, Y, Okada, N and Nakagawa, S (2008). Development of PEGylated adenoviral vector with targeting ligand. Int J Pharm 354: 3-8.
96. Byun, HM, Suh, D, Yoon, H, Kim, JM, Choi, HG, Kim, WK et al. (2004). Erythrocyte ghost-mediated gene delivery for prolonged and blood-targeted expression. Gene Ther 11: 492-496.
97. Magnani, M, Casabianca, A, Fraternale, A, Brandi, G, Gessani, S, Williams, R et al. (1996). Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection. Proc Natl Acad Sci USA 93: 4403-4408.
98. Mishra, PR and Jain, NK (2003). Folate conjugated doxorubicin-loaded membrane vesicles for improved cancer therapy. Drug Deliv 10 277-282.
99. Magnani, M, Rossi, L, Fraternale, A, Bianchi, M, Antonelli, A, Crinelli, R et al. (2002). Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther 9: 749-751.
100. Chiarantini, L, Cerasi, A, Fraternale, A, Andreoni, F, Scarí, S, Giovine, M et al. (2002). Inhibition of macrophage iNOS by selective targeting of antisense PNA. Biochemistry 41: 8471-8477.
101. Doberstein, SK, Wiegand, G, Machesky, LM and Pollard, TD (1995). Fluorescent erythrocyte ghosts as standards for quantitative flow cytometry. Cytometry 20: 14-18.
102. Magnani, M, Rossi, L, D'ascenzo, M, Panzani, I, Bigi, L and Zanella, A (1998). Erythrocyte engineering for drug delivery and targeting. Biotechnol Appl Biochem 28 (Pt 1): 1-6.
103. Vanderlinde, ES, Heal, JM and Blumberg, N (2002). Autologous transfusion. BMJ 324: 772-775.
104. Gressner, OA, Lahme, B, Koch, M and Gressner, AM (2008). Evaluation of hepatotropic targeting properties of allogenic and xenogenic erythrocyte ghosts in normal and liver-injured rats. Liver Int 28: 220-232.
105. Lucidi, V, Tozzi, AE, Bella, S and Turchetta, A (2006). A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients. BMC Pediatr 6: 17.
106. Updike, SJ and Wakamiya, RT (1982). Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences. J Lab Clin Med 101: 679-691.
107. Erchler, HG, Gasic, S, Bauer, K, Korn, A and Bacher, S (1986). In vivo clearance of antibody-sensitized human drug carrier erythrocytes. Clin Pharmacol Ther 40: 300-303.
108. Magnani, M, Rossi, L, Brandi, G, Schiavano, GF, Montroni, M and Piedimonte, G (1992). Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc Natl Acad Sci USA 89: 6477-6481.
109. Chiarantini, L, Rossi, L, Fraternale, A and Magnani, M (1995). Modulated red blood cell survival by membrane protein clustering. Mol Cel. Biochem 144: 53-59.
110. Lu, SJ, Feng, Q, Park, JS, Vida, L, Lee, BS, Strausbauch, M et al. (2008). Biological properties and enucleation of red blood cells from human embryonic stem cells. Blood 112: 4475-4484.
111. Kim, SH, Bianco, N, Menon, R, Lechman, ER, Shufesky, WJ, Morelli, AE et al. (2006). Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther 13: 289-300.
112. Kim, SH, Lechman, ER, Bianco, N, Menon, R, Keravala, A, Nash, J et al. (2005). Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 174: 6440-6448.
113. Smalheiser, NR (2007). Exosomal transfer of proteins and RNAs at synapses in the nervous system. Biol Direct 2: 35.
114. Park, IH, Arora, N, Huo, H, Maherali, N, Ahfeldt, T, Shimamura, A et al. (2008). Disease-specific induced pluripotent stem cells. Cell 134: 877-886.
115. Tjia, ST, zu Altenschildesche GM and Doerfler, W (1983). Autographa californica nuclear polyhedrosis virus (AcNPV) DNA does not persist in mass cultures of mammalian cells. Virology 125: 107-117.
116. Shoji, I, Aizaki, H, Tani, H, Ishii, K, Chiba, T, Saito, I et al. (1997). Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculoviral vectors. J Gen Virol 78: 2657-2664.
117. Hofmann, C and Strauss, M (1998). Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther 5: 531-536.
118. Hofmann, C, Hüser, A, Lehnert, W and Strauss, M (1999). Protection of baculovirus-vectors against complement-mediated inactivation by recombinant soluble complement receptor type 1. Biol Chem 380: 393-395.
119. Hüser, A, Rudolph, M and Hofmann, C (2001). Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat Biotechnol 19 451-455.
120. Sarkis, C, Serguera, C, Petres, S, Buchet, D, Ridet, JL, Edelman, L et al. (2000). Efficient transduction of neural cells in vitro and in vivo by a baculovirus-derived vector. Proc Natl Acad Sci USA 97: 14638-14643.
121. Abe, T, Takahashi, H, Hamazaki, H, Miyano-Kurosaki, N, Matsuura, Y and Takaku, H (2003). Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J Immunol 171: 1133-1139.
122. Gronowski, AM, Hilbert, DM, Sheehan, KC, Garotta, G and Schreiber, RD (1999). Baculovirus stimulates antiviral effects in mammalian cells. J Virol 73: 9944-9951.
123. Kitajima, M, Abe, T, Miyano-Kurosaki, N, Taniguchi, M, Nakayama, T and Takaku, H (2008). Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus. Mol Ther 16: 261-268.
124. Stubbs, AC, Martin, KS, Coeshott, C, Skaates, SV, Kuritzkes, DR, Bellgrau, D et al. (2001). Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7: 625-629.
125. Lutz, MB and Schuler, G (2002). Immature, semi-mature and fully mature dendritic cells: Which signals induce tolerance or immunity? Trends Immunol 23: 445-449.
126. Coura Rdos, S and Nardi, NB (2007). The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J 4 99.
127. Rivière, C, Danos, O and Douar, AM (2006). Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 13: 1300-1308.
128. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
129. Ellis, J (2005). Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 16: 1241-1246.
130. Hartman, ZC, Appledorn, DM and Amalfitano, A (2008). Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132: 1-14.
131. Ishida, T, Masuda, K, Ichikawa, T, Ichihara, M, Irimura, K and Kiwada, H (2003). Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm 255: 167-174.
132. Sakurai, H, Kawabata, K, Sakurai, F, Nakagawa, S and Mizuguchi, H (2008). Innate immune response induced by gene delivery vectors. Int J Pharm 354: 9-15.
133. Sellins, K, Fradkin, L, Liggitt, D and Dow, S (2005). Type I interferons potently suppress gene expression following gene delivery using liposome-DNA complexes. Mol Ther 12: 451-459.